
Reports Q3 revenue $1.61M, consensus $1.6M. The company said, “Caribou has not set a timeline for the completion of the review of strategic alternatives, does not intend to provide further
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CRBU | Caribou Biosciences | 0.35 | -1.54 | -81.38% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.35 | -81.38% |

Reports Q3 revenue $1.61M, consensus $1.6M. The company said, “Caribou has not set a timeline for the completion of the review of strategic alternatives, does not intend to provide further

BofA moved to No Rating on Caribou Biosciences (CRBU) after the company announced a strategic review and plans to discontinue development of vispa-cel and CB-011. The planned discontinuation of both

H.C. Wainwright downgraded Caribou Biosciences (CRBU) to Neutral from Buy without a price target The company is exploring strategic alternatives as all of its clinical programs are halted, the analyst

Shares in Caribou Biosciences ($CRBU) plunged over 43% today as investors reacted to the company’s decision to potentially put itself up for sale and slash jobs because of a lack

Leerink downgraded Caribou Biosciences (CRBU) to Market Perform from Outperform with a price target of $1, down from $4. The firm cites decreased visibility into Caribou’s outlook as an ongoing

RBC Capital analyst Luca Issi downgraded Caribou Biosciences (CRBU) to Sector Perform from Outperform with a price target of $1, down from $10. The company is exploring strategic alternatives and

Retreat in Oil prices and Treasury yields helped support investor sentiment, sending Nasdaq Composite and the S&P 500 to record highs. Utilities was the best performing sector in the index,

Brookline downgraded Caribou Biosciences (CRBU) to Hold from Buy after the company said it is evaluating strategic alternatives. Published first on TheFly – the ultimate source for real-time, market-moving breaking

The latest announcement is out from Caribou Biosciences ( ($CRBU) ). On October 2, 2026, Caribou Biosciences’ board approved a broad restructuring as it begins evaluating strategic alternatives, including possible

16:25 EDT Caribou Biosciences (CRBU) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >>
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 11, 2027TBA | $38.12M | $-0.10 | $1.70M | 0.28 | -0.34 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.